Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Aldeyra Therapeutics, Inc.
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Aldeyra Therapeutics, Inc. |
| [18-March-2026] |
MILWAUKEE, March 18, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Aldeyra (Nasdaq: ALD). The investigation results from inaccurate statements Aldeyra may have made regarding its financial statements, business operations and prospects.
Click here to join our investigation or to obtain additional information, or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. The investigation focuses on whether Aldeyra disclosed problems in its clinical trials for reproxalap for dry eye disease. We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Contact:
SOURCE Ademi LLP | ||
Company Codes: NASDAQ-CM:ALD |
View original content to download multimedia:
